Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.92 USD | +0.32% | -2.62% | -38.58% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-38.58% | 1.06B | B | ||
-3.87% | 187B | C+ | ||
-0.52% | 109B | C | ||
-3.65% | 69.22B | A | ||
-5.79% | 46.36B | B- | ||
+13.26% | 46.19B | B- | ||
+6.21% | 42.44B | B+ | ||
+18.83% | 30.84B | B | ||
+17.29% | 25.73B | A- | ||
-6.80% | 23.3B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ATRC Stock
- Ratings AtriCure, Inc.